Article info

Original research
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Authors

  1. Correspondence to Dr Anna Minchom; anna.minchom{at}icr.ac.uk
View Full Text

Citation

Papadatos-Pastos D, Yuan W, Pal A, et al
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Publication history

  • Accepted March 15, 2022
  • First published June 18, 2022.
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.